Congenica and UK Alliance Partner
News May 13, 2015
According to the pair, their partnership will foster the development of additional collaboration between Congenica and other universities and NHS hospital Trusts in the north of England.
The first proof-of-principle agreement under the partnership has already been formed between Congenica and Central Manchester University Hospitals NHS Foundation Trust. Under the terms of their agreement, the partners plan to create a reference laboratory that will be based at the Manchester Centre for Genomic Medicine that will handle genome screening of patients and their unaffected relatives to generate comprehensive genetic profiles and clinical reports. Initial efforts will focus on developmental disorders, but will eventually be expanded to include programs in other therapeutic indications, such as ophthalmological, cardiovascular, and neurological disease.
The partners will also work on developing and implementing next-generation sequencing data analysis pipelines, as well as on genome-wide interpretation and reporting tools for diagnostic testing. They'll use Congenica's genome analytics platform, which uses statistical and computational methods to analyze and process data from thousands of samples per year. The planned system will be rolled out to a variety of different applications and will be available through service and licensing business models.
"This is a great opportunity to bring together the wealth of clinical expertise and innovation at Manchester with our scalable genome analytics and clinical decision support tools," Tom Weaver, CEO of Congenica, said in a statement. "We strongly believe that partnering is the best way to facilitate rapid adoption of our technology and make a real impact on tackling genetic disease in the clinic."
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018